February 10, 2023 — GE HealthCare, a leading global precision care innovator, announced that it has signed an agreement to acquire Caption Health, Inc., a privately owned artificial intelligence (AI) healthcare leader that creates clinical applications to aid in early disease detection, using AI to assist in conducting ultrasou
If you enjoy this content, please share it with a colleague
Many cardiology departments face significant challenges meeting regulatory requirements, quality metrics, and productivity goals. Mastering these challenges is increasingly important as pay-for-performance efforts and value-based payment models become more common. Your workflow solution should improve your department’s productivity and efficiency.
If you enjoy this content, please share it with a colleague
February 9, 2023 — Imperative Care, a medical technology company developing connected innovations to elevate care for people affected by vascular diseases, today announced the formation of
February 9, 2023 — The Cardiomatics certified online SaaS platform provides world-class Holter ECG analytics to support cardiac care. Its advanced algorithms have been validated in various clinical trials and used commercially by hundreds of cardiologists and general practitioners from over 15 countries around the world, including Germany, Switzerland, Poland and the United Kingdom.
February 8, 2023 —Medtronic announced late-breaking clinical data from the STROKE AF clinical study, which showed large and small vessel disease stroke patients had a 10-fold increase in AF detection with the
February 8, 2023 — Carestream Health is partnering with Robarts Research Institute to increase and demonstrate the clinical value of digital X-ray, digital tomosynthesis and dual energy technologies to help improve the outcomes of patients with cardiothoracic and pulmonary diseases. Carestream is providing a state-of-the-art imaging system and software to Robarts, the research institute of Schulich School of Medicine & Dentistry at
February 8, 2023 — Results of research that identified new causes of Atherosclerotic Coronary Artery Disease, or ASCAD, have been reported by G3 Therapeutics (Global Genomics Group) and Aitia.
